GLP1 Academy

Research library

GLP-1 Research Library

Plain-English summaries of the studies that matter most. Every summary lists the study, publication, participants, major findings, important limitations, what it means for you, and a link to the original research.

Summaries are educational, not medical advice. Study results describe averages in selected groups — your situation is individual, and treatment decisions belong with your clinician.

01

Weight Loss

The largest and best-known body of GLP-1 research: how much weight people lose on average, and how the medications compare.

New England Journal of Medicine·2021·Randomized controlled trial

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

Who was studied
1,961 adults with obesity or overweight, without diabetes
What it found
Adults taking semaglutide 2.4 mg weekly lost an average of about 15% of their body weight over 68 weeks, compared with about 2.4% on placebo. Both groups received lifestyle counseling.
Important limitations
Participants were mostly white and female; results reflect averages, and individual results vary widely. Weight regain is common after stopping.
What it means for you
This is the landmark trial that established semaglutide 2.4 mg (Wegovy) for chronic weight management. It set the benchmark other medications are compared against.
Read the original research →
New England Journal of Medicine·2022·Randomized controlled trial

Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

Who was studied
2,539 adults with obesity or overweight, without diabetes
What it found
Adults taking tirzepatide lost an average of 15–21% of body weight over 72 weeks depending on dose, versus about 3% on placebo. The highest dose produced the largest average loss seen in a major obesity drug trial at the time.
Important limitations
As with other trials, participants received lifestyle support, and the study population may not reflect all patients. Long-term maintenance after stopping was not measured here.
What it means for you
Tirzepatide (Zepbound/Mounjaro) acts on two hormone pathways (GIP and GLP-1) and showed the largest average weight loss of any approved medication in a major trial.
Read the original research →
Diabetes, Obesity and Metabolism·2022·Trial extension study

Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide (STEP 1 Extension)

Who was studied
327 participants from the STEP 1 trial followed after treatment stopped
What it found
One year after stopping semaglutide, participants regained about two-thirds of the weight they had lost. Improvements in blood pressure, blood sugar and cholesterol also largely reversed.
Important limitations
Follow-up was only one year; the study could not distinguish medication effects from lifestyle changes after withdrawal.
What it means for you
GLP-1 medications work while you take them. Obesity is increasingly understood as a chronic condition, and stopping treatment usually means regaining weight — an important factor in deciding whether to start.
Read the original research →
02

Cardiovascular Health

Some GLP-1 medications are proven to reduce heart attacks, strokes and cardiovascular death — not just weight.

New England Journal of Medicine·2023·Randomized controlled trial

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)

Who was studied
17,604 adults with existing cardiovascular disease and overweight/obesity, without diabetes
What it found
Semaglutide 2.4 mg reduced the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% compared with placebo over about 3 years.
Important limitations
Participants already had heart disease, so results may not apply to people at lower risk. The trial was not designed to separate weight-loss effects from other mechanisms.
What it means for you
This was the first trial to show a weight-loss medication directly prevents heart attacks and strokes — a major reason GLP-1s are now discussed as cardiovascular drugs, not just weight-loss drugs.
Read the original research →
New England Journal of Medicine·2016·Randomized controlled trial

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER)

Who was studied
9,340 adults with type 2 diabetes at high cardiovascular risk
What it found
Liraglutide reduced major cardiovascular events by 13% and cardiovascular death by 22% compared with placebo over about 3.8 years.
Important limitations
Studied only people with type 2 diabetes at high risk; the daily injection and older drug are less commonly used for weight management today.
What it means for you
LEADER was the first major trial to prove a GLP-1 medication protects the heart, opening the door to the larger trials that followed.
Read the original research →
New England Journal of Medicine·2023·Randomized controlled trial

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)

Who was studied
529 adults with obesity and a common form of heart failure (HFpEF)
What it found
Semaglutide improved symptoms, physical function and exercise capacity, and reduced weight and inflammation markers over 52 weeks.
Important limitations
One-year trial focused on symptoms and function rather than hospitalizations or survival; participants had obesity-related HFpEF specifically.
What it means for you
For people with this hard-to-treat form of heart failure, semaglutide offered meaningful symptom relief — an entirely new treatment direction now being studied further.
Read the original research →
03

Diabetes & Metabolic Health

GLP-1 medications began as diabetes drugs. This research covers blood sugar control and the metabolic effects behind the weight loss.

New England Journal of Medicine·2021·Randomized controlled trial

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)

Who was studied
1,879 adults with type 2 diabetes
What it found
Tirzepatide lowered blood sugar (HbA1c) and body weight more than semaglutide 1 mg at all doses over 40 weeks. Average weight loss reached about 11 kg at the highest dose.
Important limitations
Compared against the 1 mg diabetes dose of semaglutide, not the 2.4 mg obesity dose. Side effects (mostly digestive) were common in both groups.
What it means for you
A rare head-to-head trial showing how the two leading medications compare directly for blood sugar and weight in people with diabetes.
Read the original research →
New England Journal of Medicine·2016·Randomized controlled trial

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)

Who was studied
3,297 adults with type 2 diabetes at high cardiovascular risk
What it found
Semaglutide reduced major cardiovascular events by 26% versus placebo over about 2 years. An eye complication (retinopathy) was more common in the semaglutide group, mainly in people with pre-existing eye disease.
Important limitations
Relatively short follow-up; the retinopathy finding appeared linked to rapid blood-sugar improvement in high-risk patients.
What it means for you
Established semaglutide's heart benefits in diabetes — and a reminder that rapid metabolic improvement needs medical monitoring in people with existing complications.
Read the original research →
The Lancet / NEJM (program publications)·2021–2023·Phase 3 trial program

Tirzepatide for the Treatment of Type 2 Diabetes (SURPASS program overview)

Who was studied
Over 10,000 adults across multiple trials
What it found
Across the SURPASS trials, tirzepatide consistently improved blood sugar control and produced substantial weight loss compared with placebo, semaglutide, and insulin regimens.
Important limitations
Trial participants are selected and monitored closely; real-world results and tolerability differ. Most participants had long-standing diabetes.
What it means for you
The SURPASS program is the evidence base that established tirzepatide as one of the most effective diabetes medications available.
Read the original research →
04

Muscle & Body Composition

Rapid weight loss includes some lean mass. Researchers are studying how much muscle is lost and how to protect it.

Presented at ENDO / published analyses·2023·Trial substudy (DXA imaging analysis)

Body Composition Changes During Weight Reduction with Tirzepatide (SURMOUNT-1 substudy)

Who was studied
160 participants from SURMOUNT-1 with body-composition scans
What it found
About 25% of the weight lost on tirzepatide was lean mass (including muscle), and about 75% was fat mass. This ratio is similar to what is seen with diet-induced weight loss and bariatric surgery.
Important limitations
Small substudy; lean mass measured by DXA includes water and organ tissue, not just muscle. Strength and function were not directly measured.
What it means for you
Muscle loss during GLP-1 weight loss is real but proportional to total loss — and it makes protein intake and resistance training especially important while on these medications.
Read the original research →
Journal of Clinical Endocrinology & Metabolism (reviews)·2023–2024·Narrative review

Muscle Mass and GLP-1 Receptor Agonists: A Review of the Evidence

Who was studied
Pooled evidence from multiple trials
What it found
Reviews conclude that absolute muscle mass decreases during GLP-1 treatment, but the proportion of muscle relative to body weight typically improves. Older adults and people with low baseline muscle are at highest risk of clinically meaningful loss.
Important limitations
Few trials directly measure strength or physical function; most evidence is inferred from imaging substudies.
What it means for you
The concern about 'muscle wasting' is often overstated, but it is not zero — especially for adults over 60. Exercise and adequate protein are the evidence-based countermeasures.
Read the original research →
05

Nutrition

GLP-1s change appetite and food preferences. Research here covers what people eat on these medications and nutritional risks.

Diabetes, Obesity and Metabolism·2021·Randomized controlled substudy

Reduced Appetite and Energy Intake with Semaglutide (STEP 1 mechanism substudy)

Who was studied
72 adults from the STEP program
What it found
Semaglutide reduced calorie intake by about 35% at a test meal, lowered hunger and food cravings, and shifted preferences away from high-fat foods.
Important limitations
Small, short substudy; laboratory meal settings don't fully reflect everyday eating.
What it means for you
This is the clearest picture of how GLP-1s actually work day to day: less hunger, fewer cravings, and earlier fullness — not a 'metabolism boost.'
Read the original research →
Obesity (reviews and clinical guidance)·2023–2024·Clinical review

Nutritional Deficiencies and GLP-1 Receptor Agonists: Clinical Considerations

Who was studied
Evidence synthesis
What it found
Because people eat substantially less on GLP-1s, inadequate protein, vitamin and mineral intake is a documented risk — particularly vitamin D, B12, iron and protein. Clinical guidance recommends nutritional monitoring during treatment.
Important limitations
Direct trial data on deficiency rates are limited; most guidance is extrapolated from bariatric surgery and very-low-calorie diet research.
What it means for you
Eating less means every meal matters more. A protein-forward, nutrient-dense diet — ideally with a dietitian's input — helps prevent deficiencies during treatment.
Read the original research →
06

Kidney Health

GLP-1 medications protect the kidneys in people with diabetes — one of the most important newer findings.

New England Journal of Medicine·2024·Randomized controlled trial

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW)

Who was studied
3,533 adults with type 2 diabetes and chronic kidney disease
What it found
Semaglutide reduced the risk of major kidney outcomes (kidney failure, major loss of kidney function, or kidney/cardiovascular death) by 24% versus placebo. The trial was stopped early because the benefit was clear.
Important limitations
Studied people with diabetes-related kidney disease; benefits in kidney disease from other causes are still being studied.
What it means for you
FLOW made semaglutide the first GLP-1 proven to directly protect the kidneys — a major advance for the millions of people with diabetic kidney disease.
Read the original research →
07

Liver Health

Fatty liver disease (MASH/MASLD) is closely tied to metabolic health, and GLP-1s are among the most promising treatments being studied.

New England Journal of Medicine·2021·Randomized controlled trial

Semaglutide in Patients with Non-Alcoholic Steatohepatitis (NASH)

Who was studied
320 adults with biopsy-confirmed NASH (fatty liver with inflammation)
What it found
Semaglutide resolved NASH with no worsening of liver scarring in 59% of participants at the highest dose, versus 17% on placebo, over 72 weeks.
Important limitations
Improvement in liver fibrosis (scarring) itself was not statistically significant in this trial; longer and larger trials followed.
What it means for you
Fatty liver disease affects roughly a quarter of adults and has few approved treatments. GLP-1s are among the most promising options in development.
Read the original research →
New England Journal of Medicine·2024·Randomized controlled trial

Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis (SYNERGY-NASH)

Who was studied
190 adults with biopsy-confirmed MASH and moderate-to-severe fibrosis
What it found
Tirzepatide resolved MASH without worsening fibrosis in 44–62% of participants (versus 10% on placebo), and improved fibrosis in about half.
Important limitations
One-year trial; whether these changes reduce long-term liver failure or transplant risk remains unproven.
What it means for you
A second GLP-1-class drug showing strong effects on fatty liver disease — this is one of the fastest-moving areas of GLP-1 research.
Read the original research →
08

Brain Health

Early research explores whether GLP-1s affect the brain — from addiction and cravings to dementia risk. This is promising but preliminary.

Multiple journals (e.g., Alzheimer's & Dementia, JAMA Neurology analyses)·2022–2025·Observational studies and trial secondary analyses

GLP-1 Receptor Agonists and Risk of Dementia: Observational and Trial Evidence

Who was studied
Large health-record cohorts and pooled diabetes trials
What it found
Several large observational studies and pooled trial analyses found people with diabetes taking GLP-1 medications had lower rates of dementia diagnosis than those on other diabetes drugs. Dedicated prevention trials (such as EVOKE, testing semaglutide in early Alzheimer's disease) are underway.
Important limitations
Observational data cannot prove cause and effect; people prescribed GLP-1s may differ from others in many ways. Results from the dedicated dementia trials are still pending.
What it means for you
An exciting but unproven frontier. No GLP-1 is approved for brain health, and it is too early to take one for dementia prevention.
Read the original research →
Multiple journals (preclinical and early clinical studies)·2022–2025·Animal studies, observational data, early trials

GLP-1 Receptor Agonists and Alcohol, Nicotine and Substance Use: Emerging Evidence

Who was studied
Animal models and human observational cohorts
What it found
Animal studies consistently show GLP-1s reduce alcohol and drug-seeking behavior. Early human data — including reduced alcohol use in some observational cohorts — are encouraging, and randomized trials in alcohol use disorder are in progress.
Important limitations
Human evidence is early and mixed; no GLP-1 is approved for addiction treatment.
What it means for you
Many patients report reduced interest in alcohol on GLP-1s. Science is catching up to that anecdote, but this remains an experimental use.
Read the original research →
09

Healthy Aging

Because GLP-1s touch weight, blood sugar, heart, kidney and inflammation, researchers are asking whether they affect aging itself.

Reviews in Cell Metabolism, Nature Aging and others·2023–2025·Scientific review / perspective

GLP-1 Receptor Agonists and Hallmarks of Aging: A Research Perspective

Who was studied
Evidence synthesis across mechanistic and clinical studies
What it found
GLP-1 medications influence several biological processes linked to aging: chronic inflammation, insulin sensitivity, cardiovascular function and body composition. Some researchers have proposed them as candidate 'geroprotective' (aging-slowing) drugs.
Important limitations
No trial has tested GLP-1s for lifespan or aging outcomes in healthy people. Nearly all evidence comes from people with obesity or diabetes.
What it means for you
The longevity case for GLP-1s is biologically plausible and actively researched — but today it remains a hypothesis, not an established benefit for healthy people.
Read the original research →
Journal of the American Geriatrics Society and related reviews·2023–2024·Clinical review

Use of GLP-1 Medications in Older Adults: Efficacy and Safety Considerations

Who was studied
Adults 65+ in trial subgroups and real-world cohorts
What it found
Older adults lose weight on GLP-1s at rates similar to younger adults, but face higher risks from muscle loss, dehydration and undernutrition. Reviews recommend slower dose escalation, protein and resistance-training support, and closer monitoring.
Important limitations
Adults over 75 are underrepresented in the major trials; frailty-specific evidence is thin.
What it means for you
For adults over 60 — a core GLP-1 Academy audience — these medications can be appropriate, but the muscle-preservation and nutrition details matter more, not less.
Read the original research →
10

Safety & Side Effects

The most important research for anyone considering a GLP-1: what goes wrong, how often, and for whom.

Pooled analyses across STEP/SURMOUNT programs·2021–2023·Meta-analysis of randomized trials

Gastrointestinal Adverse Events with GLP-1 Receptor Agonists: Pooled Trial Analysis

Who was studied
Tens of thousands of trial participants
What it found
Nausea, vomiting, diarrhea and constipation are the most common side effects, typically mild-to-moderate and worst during dose increases. In major trials, roughly 4–7% of participants stopped treatment due to side effects.
Important limitations
Trial participants receive structured dose escalation and support; real-world discontinuation rates are higher.
What it means for you
Side effects are common but usually manageable with slow dose increases and dietary adjustments. Most people who stop do so early in treatment.
Read the original research →
JAMA Internal Medicine and regulatory reviews·2023–2024·Meta-analyses and pharmacovigilance studies

GLP-1 Receptor Agonists and Pancreatitis, Gallbladder and Thyroid Safety: Evidence Review

Who was studied
Pooled trials and post-marketing surveillance data
What it found
Gallbladder problems (gallstones) are modestly increased, largely tied to rapid weight loss itself. Large analyses have not confirmed a pancreatitis signal in people without prior disease. The thyroid C-cell tumor warning comes from rodent studies; human relevance remains unproven, but the drugs are avoided in people with medullary thyroid carcinoma or MEN2.
Important limitations
Rare events require enormous datasets; surveillance continues. Rodent thyroid findings may not translate to humans, but caution remains warranted.
What it means for you
The major safety questions have reassuring answers so far, with clear exceptions: personal or family history of medullary thyroid cancer or MEN2 is a firm reason not to use these drugs.
Read the original research →
Health-services research (claims database studies)·2023–2025·Observational cohort studies

Real-World Persistence and Discontinuation of GLP-1 Medications

Who was studied
Hundreds of thousands of real-world patients
What it found
In real-world data, a majority of people stop GLP-1 weight-loss treatment within one to two years — far more than in clinical trials. Cost, side effects and supply issues are leading reasons, and most weight is regained after stopping.
Important limitations
Claims data lack detail on why individuals stopped; patterns shift as coverage and supply change.
What it means for you
The gap between trial results and real life is large. Before starting, it's worth planning honestly for cost, supply and the likelihood of long-term use.
Read the original research →
11

New GLP-1 Drugs

The next generation: oral pills, triple-hormone drugs, and combinations designed for more weight loss or muscle preservation.

The Lancet·2023·Randomized controlled trial

Oral Semaglutide 25 mg in Adults with Overweight or Obesity (OASIS 1)

Who was studied
667 adults with overweight or obesity, without diabetes
What it found
A daily oral (pill) form of semaglutide produced average weight loss of about 15% over 68 weeks — comparable to the weekly injection.
Important limitations
Oral semaglutide requires strict fasting administration (empty stomach, limited water, 30-minute wait before eating); digestive side effects were common.
What it means for you
Effective GLP-1 treatment without injections is close to reality — a big deal for people who avoid needles.
Read the original research →
New England Journal of Medicine·2023·Randomized controlled phase 2 trial

Retatrutide for Obesity — A Phase 2 Trial

Who was studied
338 adults with obesity
What it found
Retatrutide — a 'triple agonist' acting on GLP-1, GIP and glucagon receptors — produced average weight loss up to about 24% over 48 weeks, the largest seen in a drug trial to date.
Important limitations
Phase 2 means a relatively small, shorter trial; larger phase 3 trials are still underway, and the drug is not approved.
What it means for you
A glimpse of where the field is heading: multi-hormone drugs with even larger effects. Not available outside clinical trials.
Read the original research →
New England Journal of Medicine·2023·Randomized controlled phase 2 trial

Orforglipron, an Oral Small-Molecule GLP-1 Agonist, in Obesity (Phase 2)

Who was studied
272 adults with obesity or overweight
What it found
Orforglipron, a once-daily pill that does not require fasting restrictions, produced up to about 15% average weight loss over 36 weeks.
Important limitations
Phase 2 results; side effects led to discontinuation in 10–17% of participants at higher doses. Not yet approved.
What it means for you
A simpler pill — no fasting rules — could make GLP-1 treatment far more accessible if phase 3 trials confirm the results.
Read the original research →
12

Research Pipeline

What's being studied right now: the trials and indications that could reshape what GLP-1 medicines are used for.

New England Journal of Medicine·2024·Randomized controlled trial

GLP-1 Medications for Sleep Apnea (SURMOUNT-OSA)

Who was studied
469 adults with obesity and moderate-to-severe obstructive sleep apnea
What it found
Tirzepatide reduced the severity of sleep apnea dramatically — by about 20–24 breathing events per hour versus about 4–5 on placebo — alongside substantial weight loss. Many participants no longer met criteria for sleep apnea treatment.
Important limitations
Benefits are tied to weight loss; long-term outcomes and effects in people without obesity are unknown.
What it means for you
This led to the first approval of a medication (tirzepatide) specifically for obstructive sleep apnea in adults with obesity — expect more 'beyond weight' approvals like this.
Read the original research →
Ongoing trials registered at ClinicalTrials.gov·Ongoing·Ongoing and recruiting clinical trials

Active Research Areas: Addiction, Alzheimer's, PCOS, and Osteoarthritis

Who was studied
Various
What it found
Hundreds of trials are testing GLP-1s for conditions including alcohol use disorder, early Alzheimer's disease, polycystic ovary syndrome, knee osteoarthritis, and heart failure. Early results in knee osteoarthritis (semaglutide reduced pain and improved function in a 2024 NEJM trial) have been positive.
Important limitations
Most of these uses are years from possible approval; many will not succeed. 'In trials' does not mean 'proven.'
What it means for you
The GLP-1 story is still being written. Following the pipeline helps you understand what these medicines may — and may not — do in the future.
Read the original research →